Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Share News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Vernalis Non-Executive Buys 103,000 Shares

Tue, 14th Oct 2014 15:08

LONDON (Alliance News) - Vernalis PLC Tuesday said Non-Executive Director Nigel Sheail bought 103,000 shares at a price of 48.7 pence per share Monday.

Sheail is now the beneficial holder of 210,000 shares, representing 0.047% of the company's current issued share capital.

Shares in the research and development company were up 1.8% at 49.00 pence Tuesday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
10 Feb 2015 09:07

Vernalis Posts Narrowed Loss On Dollar Strength And Lower Costs

Read more
10 Feb 2015 06:16

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Feb 2015 16:13

REPEAT: UK Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Feb 2015 16:05

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Feb 2015 12:10

UK MIDDAY BRIEFING: Fewer Imports By World's Two Big Exporters

Read more
9 Feb 2015 06:15

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
6 Feb 2015 16:01

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
6 Feb 2015 06:17

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
5 Feb 2015 16:00

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
5 Feb 2015 06:24

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
4 Feb 2015 15:58

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
4 Feb 2015 06:15

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
3 Feb 2015 16:00

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
19 Dec 2014 08:14

Vernalis shares stumble as Novartis abandons work on drug

LONDON, Dec 19 (Reuters) - Shares in Vernalis fell sharply on Friday as Swiss drugmaker Novartis stopped development work on a drug licensed from the British biotech company 10 years ago. Vernalis said Novartis had handed back rights to AUY922 after studying it as a treatment for a range of

Read more
14 Nov 2014 19:34

Friday broker round-up:

TSB Banking: Shore Capital reiterates buy with a target price for 325p. Vernalis: Canaccord Genuity ups target to 66p from 56p and reiterates buy. Aggreko: Panmure Gordon and Investec reiterate hold. Gemfields: Numis initiates coverage with a buy recommendation and 70p target price. Ithaca Energy

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.